Abstract

CUBAS, Santiago et al. The best of the 2019 AHA/ACC Congress. Rev.Urug.Cardiol. [online]. 2020, vol.35, n.1, pp.249-269.  Epub Apr 01, 2020. ISSN 0797-0048.  https://doi.org/10.29277/cardio.35.1.13.

A new meeting of the annual congress of the American College of Cardiology, was held from November 16 to 18 last year; located in the city of Philadelphia. As one of the most important events in global cardiology, it was attended by leading professionals who were the last clinical trials in the Late Breaking Science sessions, which addressed different aspects of the specialty: innovative strategies to reduce cardiovascular risk, results of the trials of ischemia, controversies in the contemporary management of aortic stenosis, state of the art of the management of patients with acute coronary syndromes, challenges in heart failure and new frontiers in lipid therapy.

We will make a brief summary of the main presented trials:

- The Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF).

- The COLchicine Cardiovascular Outcomes Trial (COLCOT).

- Global Comparison of a Rivaroxaban-Based Antithrombotic Strategy versus an Antiplatelet-Based Strategy After Transcathether Aortic Replacement to Optimize Clinical Outcomes (GALILEO) Trial: Primary Results.

- RECOVERY: Early Surgery versus Conventional Management for Asymptomatic Severe Aortic Stenosis.

- International Study of Comparative Health Effectiveness With Medical and Invasive Approaches: Primary Report of Clinical Outcomes (ISCHEMIA).

Keywords : DAPA-HF; COLCOT; GALILEO; RECOVERY; ISCHEMIA.

        · abstract in Spanish | Portuguese     · text in Spanish     · Spanish ( pdf )